Posts

AstraZeneca's Tozorakimab Achieves Phase 3 Success in Broader COPD Population

on
AstraZeneca's anti-IL-33 antibody tozorakimab met its primary endpoint in the Phase 3 Oberon and Titania trials, significantly reducing the annualized rate of moderate-to-severe COPD exacerbations compared to placebo. 1 3 Success was observed in a broader-than-expected population, including former and current smokers across all blood eosinophil counts and lung function severity stages. 1 2 3 Tozorakimab demonstrated a favorable safety profile and was generally well-tolerated. 1 3 Unlike competitors like Sanofi/Regeneron's itepekimab and Roche's astegolimab, which had mixed results, tozorakimab showed consistent efficacy across trials. 1 3 Topline results announced on March 27, 2026; full data to be presented at an upcoming medical meeting. 1 3 AstraZeneca is conducting additional Phase 3 trials (Prospero and Miranda) in COPD, with results expected in the first half of 2026. 1 3 Analysts highlight tozorakimab's potential for peak sales of $3-5 billion and bro...

AstraZeneca's In Vivo CAR-T ESO-T01 Shows Promise in Multiple Myeloma with Remissions but One Death in China Trial

on

Kailera Therapeutics Files for Nasdaq IPO to Fund Obesity Drug Pipeline Licensed from China Partner

on

Anumana Secures FDA Clearance for First-of-Its-Kind ECG-AI Algorithm for Early Detection of Pulmonary Hypertension

on

FDA Approves Novo Nordisk's Awiqli: First Once-Weekly Basal Insulin for Type 2 Diabetes

on

Recordati Confirms Non-Binding €10.9 Billion Full Takeover Offer from CVC Capital Partners

on

"We need to put some bad ideas to bed": Inside Incubate's battles for biotech on Capitol Hill

on

Novartis Agrees to Acquire Excellergy for Up to $2 Billion to Bolster Allergy Portfolio with Potential Xolair Successor

on

FDA Approves Rocket Pharma's Kresladi Gene Therapy for Ultra-Rare LAD-I After Setbacks

on

Beam's Base Editor Advances to Pivotal Development on Back of Impressive AATD Data

on

Pinnacle Medicines Secures $89M Series B Funding for Oral Peptide Pipeline

on

Kodiak Sciences' Zenkuda Succeeds in Second Phase 3 Trial for Diabetic Retinopathy

on

First Patient Dosed in Phase 1b/2 Trial of HLX701 Combination Therapy for Advanced Colorectal Cancer

on